Ultragenyx Pharmaceutical NASDAQ: RARE expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference.
CEO Emil Kakkis said the company is heading toward $1 billion in revenue next year and expects “meaningful profitability.” The outlook follows setbacks in its setrusumab program for osteogenesis imperfecta, or OI, and its Angelman syndrome program. Ultragenyx plans to continue pursuing setrusumab but has set aside the Angelman program, he said.
The company has reduced its staff by approximately 20% and cut research and development spending by 50%, Kakkis said. It also sold two priority review vouchers for approximately $350 million, bringing its cash balance to more than $700 million, he said.
Profitability and Commercial Growth
CFO Howard Horn said Ultragenyx projects profitability in 2027 and intends to sustain it. The company plans to keep R&D spending below $350 million and selling, general and administrative expenses below $375 million next year.
The forecast includes the possibility of another setrusumab trial, Horn said. He added that the company has sufficient balance-sheet strength to reach profitability without raising additional capital.
Horn said the company’s existing four-product business has historically grown by more than 20% annually, although he did not provide a growth forecast. Kakkis pointed to expansion into additional territories, including Japan and the Middle East, as a contributor to that growth.
Asked about potential competition for Crysvita after patent expiration, Kakkis said Ultragenyx and partner Kyowa Kirin are working on potential next-generation versions. The companies hope to improve properties such as potency or dosing intervals, he said.
Gene Therapy Launches
Kakkis said the launches of FAYUVI and GENGLYCOS are going well, with more immediate interest in FAYUVI from families affected by Sanfilippo syndrome. He said the company plans to provide launch information in January, including treatment-center, patient-start and revenue figures.
Ultragenyx does not plan to issue product-specific forecasts for the two therapies until it has approximately six quarters of launch experience, Kakkis said. Horn said the company has not provided guidance for the launches, but that extrapolating normal growth from the existing business would leave a relatively small revenue contribution needed from the two gene therapies to support profitability.
Setrusumab Discussions Continue
Kakkis said Ultragenyx is discussing next steps for setrusumab with the Food and Drug Administration after the ORBIT study missed its fracture-rate endpoint. He attributed the result in part to a lower-than-expected fracture rate among enrolled patients.
The CEO pointed to improvements in bone mineral density and other measures, as well as a post hoc analysis showing fracture reductions among patients with higher baseline fracture rates. He said patients had been assigned to groups based on fracture history, but the subset analysis itself was not prespecified for statistical analysis.
Kakkis cautioned that bone mineral density is not currently accepted by the FDA as a surrogate endpoint for OI. While the company is exploring alternatives, he said investors should not assume a further trial would occur only after approval. If another study is needed, it would probably resemble the COSMIC study’s active-comparator design, he said. He did not provide a timeline for an FDA update.
OTC Gene Therapy
Ultragenyx is also studying DTX301, a gene therapy for ornithine transcarbamylase deficiency, in the open-label portion of its Phase 3 study. Kakkis said the company is assessing whether some patients can discontinue existing drugs and dietary restrictions while maintaining disease control.
He said the blinded portion showed improved ammonia control and patient-reported outcomes, and argued that those data should support approval. The open-label portion is intended to provide further information on whether patients can safely move away from current care, he said.
About Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.